BACKGROUND: Osteoporosis in black women may result in increased disability, longer hospital stays, and higher mortality compared with white women. However, it is unknown whether osteoporosis treatment or bone mineral density (BMD) measurement is different in these women, particularly in those at highest risk. METHODS: To examine differences and determinants of osteoporosis preventive interventions among white and black women in a large regional health maintenance organization, women 50 years of age and older were surveyed (n = 8,909) to determine their receipt of BMD testing and medical therapies for osteoporosis prevention. RESULTS: After adjusting for potential confounders, black women had two- to threefold lower odds of BMD test or osteoporosis prescription treatment. Even among women with a previous fracture, blacks still had a significantly lower likelihood of both BMD testing and prescription therapy. CONCLUSION: Compared with whites, black women reported significantly less BMD testing and prescription and nonprescription osteoporosis therapy. This disparity was not fully explained by other demographic or risk factor differences.
BACKGROUND:Osteoporosis in black women may result in increased disability, longer hospital stays, and higher mortality compared with white women. However, it is unknown whether osteoporosis treatment or bone mineral density (BMD) measurement is different in these women, particularly in those at highest risk. METHODS: To examine differences and determinants of osteoporosis preventive interventions among white and black women in a large regional health maintenance organization, women 50 years of age and older were surveyed (n = 8,909) to determine their receipt of BMD testing and medical therapies for osteoporosis prevention. RESULTS: After adjusting for potential confounders, black women had two- to threefold lower odds of BMD test or osteoporosis prescription treatment. Even among women with a previous fracture, blacks still had a significantly lower likelihood of both BMD testing and prescription therapy. CONCLUSION: Compared with whites, black women reported significantly less BMD testing and prescription and nonprescription osteoporosis therapy. This disparity was not fully explained by other demographic or risk factor differences.
Authors: Redonda G Miller; Bimal H Ashar; Jennifer Cohen; Melissa Camp; Carmen Coombs; Elizabeth Johnson; Christine R Schneyer Journal: J Gen Intern Med Date: 2005-09 Impact factor: 5.128
Authors: Amy H Warriner; Ryan C Outman; Adrianne C Feldstein; Douglas W Roblin; Jeroan J Allison; Jeffrey R Curtis; David T Redden; Mary M Rix; Brandi E Robinson; Ana G Rosales; Monika M Safford; Kenneth G Saag Journal: Med Care Date: 2014-08 Impact factor: 2.983
Authors: Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton Journal: J Clin Endocrinol Metab Date: 2012-06-22 Impact factor: 5.958
Authors: Joan M Neuner; Xu Zhang; Rodney Sparapani; Purushottam W Laud; Ann B Nattinger Journal: J Gen Intern Med Date: 2007-06-27 Impact factor: 5.128
Authors: Jeffrey R Curtis; Fenglong Xie; Lang Chen; Paul Muntner; Carlos G Grijalva; Claire Spettell; Joaquim Fernandes; Raechele M McMahan; John W Baddley; Kenneth G Saag; Timothy Beukelman; Elizabeth Delzell Journal: Arthritis Care Res (Hoboken) Date: 2012-10 Impact factor: 4.794